Shenzhen Yinguan Biotechnology

Shenzhen Yinguan Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of mRNA-based therapeutics and vaccines. Headquartered in Shenzhen, China, the company has established a comprehensive technology platform encompassing mRNA sequence optimization, proprietary lipid nanoparticle (LNP) delivery systems, and large-scale GMP manufacturing. Its pipeline primarily targets infectious diseases, including vaccines for COVID-19, respiratory syncytial virus (RSV), and influenza, as well as oncology applications such as personalized cancer vaccines. Yinguan Bio integrates molecular biology, bioinformatics, and advanced manufacturing to accelerate the transition of genetic medicines from laboratory to clinical application. The company aims to leverage its integrated R&D capabilities to provide innovative genetic medicines with improved safety and efficacy profiles.